anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Endometriosis is a serious health problem among women of reproductive age, with pelvic pain and infertility. Given the limited success of current treatments, this study explores Neroli oil (N.O.) effects on inflammation, oxidation, angiogenesis, and tissue remodeling implicated in endometriosis.
MATERIALS AND METHODS: Albino Wistar female rats were used to simulate an endometriosis model. Groups were established for comparison: a control, an endometriosis model, a N.O.-treated group, and a N.O.-treated group postendometriosis induction. The study focused on Tumor necrosis factor-alpha (TNF-α), Interleukin 6, Interleukin 8, vascular endothelial growth factor (VEGF), myeloperoxidase, Matrix metalloproteinase-1 (MMP-1), nitric oxide, superoxide dismutase, catalase, and anti-mullerian hormone values, as well as histopathological evaluations of endometriotic foci.
RESULTS: AMH values showed a significant increase in the endometriosis group treated with N.O. compared with the endometriosis group (p < 0,01).A statistically significant decrease was found in MMP-1 level in the endometriosis group that underwent N.O. (p < 0.001). Increased CAT (p < 0.0001) and decrease in nitric oxide (p < 0.01) are found in N.O.-treated endometriosis group. TNF-α levels in the endometriosis group showed a statistically significant increase in the endometriosis group when compared with the control and sham group (p < 0.001, p < 0.01 respectively). In our study, a statistically significant increase was observed in VEGF levels (p < 0.001) in endometriosis group and significant decrease in the N.O. administered endometriosis model group. Groups treated with N.O. showed decreased inflammation and congestion scores. Histopathological assessments demonstrated reduced inflammation and tissue remodeling signs in endometriotic foci.
CONCLUSION: This study highlights the potential of N.O. in the treatment of endometriosis, owing to its anti-inflammatory, antioxidant, and antiangiogenic properties that can disrupt chronic processes. Our findings lend support to utilization of herbal remedies for the management of endometriosis, thereby emphasizing the necessity for additional comprehensive investigations in the future.
The 1 mL and 2 mL Midazolam Injection vials include a cautionary label that extends above the main label and highlights the drug name and strength per total volume. The purpose of the extended label is to prevent medication errors due to the different strengths of Midazolam Injection. Read the label and confirm you have selected the correct medication and strength. Then locate the “Tear Here” point on the label, and remove this cautionary label prior to removing the flip-off cap.

Midazolam is a potent sedative agent that requires slow administration and individualization of dosage. Clinical experience has shown midazolam to be 3 to 4 times as potent per mg as diazepam. BECAUSE SERIOUS AND LIFE-THREATENING CARDIORESPIRATORY ADVERSE EVENTS HAVE BEEN REPORTED, PROVISION FOR MONITORING, DETECTION AND CORRECTION OF THESE REACTIONS MUST BE MADE FOR EVERY PATIENT TO WHOM MIDAZOLAM INJECTION IS ADMINISTERED, REGARDLESS OF AGE OR HEALTH STATUS. Excessive single doses or rapid intravenous administration may result in respiratory depression, airway obstruction and/or arrest. The potential for these latter effects is increased in debilitated patients, those receiving concomitant medications capable of depressing the CNS, and patients without an endotracheal tube but undergoing a procedure involving the upper airway such as endoscopy or dental (see BOX WARNING and WARNINGS.)

Reactions such as agitation, involuntary movements, hyperactivity and combativeness have been reported in adult and pediatric patients. Should such reactions occur, caution should be exercised before continuing administration of midazolam (see WARNINGS).

Midazolam Injection should only be administered IM or IV (see WARNINGS).

Care should be taken to avoid intra-arterial injection or extravasation (see WARNINGS).

Midazolam Injection may be mixed in the same syringe with the following frequently used premedications: morphine sulfate, meperidine, atropine sulfate or scopolamine. Midazolam, at a concentration of 0.5 mg/mL, is compatible with 5% dextrose in water and 0.9% sodium chloride for up to 24 hours and with lactated Ringer’s solution for up to 4 hours. Both the 1 mg/mL and 5 mg/mL formulations of midazolam may be diluted with 0.9% sodium chloride or 5% dextrose in water.
Systems and methods for whitening teeth. The method may include making trays for a patient and providing the patient with instructions and products for at home whitening. The method may include performing at home nighttime whitening using carbamide peroxide, or any other whitening product that breaks down slowly. The method may include performing at home daytime whitening using hydrogen peroxide, or any other whitening product that breaks down quickly. The daytime whitening may use a chemically accelerated hydrogen peroxide or a mixture of hydrogen peroxide and carbamide peroxide. The at home daytime whitening may be performed at least partially concurrently with the at home nighttime whitening. The at home daytime whitening may be performed after the at home nighttime whitening.
FIELD: medicine, oncology, immunology. SUBSTANCE: invention relates to immunogenic composition based on TLP. Composition comprises at least one protein among TLP (Tumor Liberated Particles or particles released by tumor) or its fragment and, in part, with compositions where indicated fragments can comprise at least one of claimed peptides, given three sequences designated for treatment of cancer diseases and, in part, for treatment of non-small-cell lung cancer and urogenital system cancer in mammals. The advantage of invention involves development of novel therapeutic agents able to direct immune response for control of tumor cells. EFFECT: enhanced effectiveness of composition, valuable antitumor properties. 21 cl, 5 tbl, 2 dwg, 1 ex
Pramlintide is an analog of human amylin. Amylin is colocated with insulin in secretory granules and cosecreted with insulin by pancreatic beta cells in response to food intake. Amylin and insulin show similar fasting and postprandial patterns in healthy individuals (Figure 1).

In patients with type 1 and type 2 diabetes, there is reduced secretion from pancreatic beta cells of both insulin and amylin in response to food.

Amylin affects the rate of postprandial glucose appearance through a variety of mechanisms, as determined by nonclinical studies. Amylin slows gastric emptying (i.e., the rate at which food is released from the stomach to the small intestine) without altering the overall absorption of nutrients. In addition, amylin suppresses glucagon secretion (not normalized by insulin alone), which leads to suppression of endogenous glucose output from the liver. Amylin also regulates food intake due to centrally-mediated modulation of appetite.

In human studies, pramlintide, acting as an amylin analog, slows gastric emptying, reduces the postprandial rise in plasma glucagon, and modulates satiety leading to decreased caloric intake.
1. Technical Result Increase in efficiency of biodistribution in an organism. 2. Essence A composition of the formula or its pharmaceutically acceptable salts, multimers: prodrugs or active metabolites and compound of the formula (1) (wherein R1 - R9, X and het have the value indicated in the description), pharmaceutical composition containing the same and use thereof to obtain the medicament for regulation of gonadotropin secretion with mammalians. 3. Field of Application Medicine.
PURPOSE: To obtain the phosphate ion-adsorbing agent for oral administration, containing a ferric ion type strongly acidic cation exchange resin as an active ingredient, useful for treating and preventing hyperphosphatemia, not causing a side effect, and having a high phosphorus-removing ability. CONSTITUTION: The phosphate ion-adsorbing agent contains as an active ingredient a ferric ion type strongly acidic cation exchange resin prepared by making ferric ions carried on a gel type styrene-divinylbenzene copolymer sulfonate having a particle diameter of 20-150μm. The carrying treatment of the ferric ions is performed by adding a Na or Ca type strongly acidic cation exchange resin to the aqueous solution of a ferric chloride (e.g. FeCl3 ) with stirring or by allowing the aqueous solution to pass through a column filled with the Na or Ca type strongly acidic cation exchange resin. The ferric ions are suitably carried on the resin in an amount of 40-80mg Fe/g-Dry-R.  Since the objective adsorbing agent has high selectivity and high adsorption power for the phosphate ions and does not contain aluminum in the structure, side effects such as aluminum osteopathia or aluminum encephalopathia due to the accumulation of aluminum ions.
Participants will receive E7090 tablets, orally, once daily in 28 days cycle. Each cycle length =28 days.
The hypothesis of this study is that exposure to PEMF alters the cytokine environment of OA joints associated with a reduction of inflammation and improved homeostasis of the extracellular matrix (ECM), both potentially effecting symptomatic relief of OA pain, reducing cartilage breakdown, stimulate new cartilage formation therefore preserving joint structure. The primary objective of this study is to prospectively determine, at 12 months post treatment, the safety and efficacy of treating OA of the knee with PEMF. Safety will be assessed through adverse event collection. Study subjects will be randomized in a 2:1 ratio (active: placebo control) to either an active or placebo control (inactive) Physio-Stim device. The study is powered to detect a significant difference between groups when 120 subjects (80 active: 40 placebo control) have completed the study. Planned enrollment for the study is 150 subjects, to allow for an attrition rate of 20%.
The invention relates to a Simulium bannaense antibacterial peptide SibaCec, and genes and applications thereof, and belongs to the technical field of biomedicine. The Simulium bannaense antibacterial peptide SibaCec is a straight chain polypeptide containing 34 amino acid residues; the molecular weight is 3432.12 Da; and isoelectric point is 10.73. The genes used for coding a precursor of the Simulium bannaense antibacterial peptide SibaCec are characterized in that: GenBank accession KT223121 is composed of 272 nucleotide sequences, and the nucleotide sequence is represented by SEQ ID NO:2; the 70 to 171th nucleotides are used for coding the mature sequence of the Simulium bannaense antibacterial peptide SibaCec, and the amino acid sequence is represented by SEQ ID NO:1. The invention also discloses applications of the Simulium bannaense antibacterial peptide SibaCec in preparation of medicines used for treating pathogenic microorganism infection diseases. The coding genes of the Simulium bannaense antibacterial peptide SibaCec are obtained via cloning, and the Simulium bannaense antibacterial peptide SibaCec is obtained via chemical synthesis. The Simulium bannaense antibacterial peptide SibaCec possesses excellent killing effects on escherichia coli, pseudomonas aeruginosa, salmonella typhimurium, and acinetobacter baumannii, and is low in molecular weight, simple in structure, and low in hemolytic activity; and a preparation method is simple.
The present invention is to solve all the disadvantages and problems of the prior art as described above. The present invention relates to a simulation system and method for dental patient consultation. The shape of teeth, shape correction, and complex functions are added to provide a 3D program that enables overall consultation including the selection of prostheses. The interactive output support solution of consultation contents and a server are constructed. When a patient with damaged teeth visits the dentist, a comprehensive dental solution system that can provide stable service is used. The front picture of the patient and a picture wearing an opener are taken with a program for the virtual image of the patient. And then, the tooth part of the patient is extracted from the opener picture of the program to correct and store the damaged tooth image. The tooth part of the patient is extracted from the front picture. It is replaced with a corrected tooth image to show an appearance after the virtual tooth treatment. The simulation system includes an electronic chart of a PC; a mobile electronic chart; a virtual image simulation program; a 3D model viewer program; and a server.
Subjects will receive 05 sessions of tDCS sham and EAC.The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
BACKGROUND: Femoral head collapse is a critical pathological change and is regarded as turning point in disease progression in osteonecrosis of the femoral head (ONFH). In this study, we aim to build an automatic femoral head collapse prediction pipeline for ONFH based on magnetic resonance imaging (MRI) radiomics.
METHODS: In the segmentation model development dataset, T1-weighted MRI of 222 hips from two hospitals were retrospectively collected and randomly split into training (n = 190) and test (n = 32) sets. In the prognosis prediction model development dataset, 206 hips were also retrospectively collected from two hospitals and divided into training set (n = 155) and external test set (n = 51) according to data source. A deep learning model for automatic lesion segmentation was trained with nnU-Net, from which three-dimensional regions of interest were segmented and a total of 107 radiomics features were extracted. After intra-class correlation coefficients screening, feature correlation coefficient screening and Least Absolute Shrinkage and Selection Operator regression feature selection, a machine learning model for ONFH prognosis prediction was trained with Logistic Regression (LR) and Light Gradient Boosting Machine (LightGBM) algorithm.
RESULTS: The segmentation model achieved an average dice similarity coefficient of 0.848 and an average 95% Hausdorff distance of 3.794 in the test set, compared to the manual segmentation results. After feature selection, nine radiomics features were included in the prognosis prediction model. External test showed that the LightGBM model exhibited acceptable predictive performance. The area under the curve (AUC) of the prediction model was 0.851 (95% CI: 0.7268-0.9752), with an accuracy of 0.765, sensitivity of 0.833, and specificity of 0.727. Decision curve analysis showed that the LightGBM model exhibited favorable clinical utility.
CONCLUSION: This study presents an automated pipeline for predicting femoral head collapse in ONFH with acceptable performance. Further research is necessary to determine the clinical applicability of this radiomics-based approach and to assess its potential to assist in treatment decision-making for ONFH.
PURPOSE:To provide the titled preparation having sufficiently high quality, usable conveniently, and capable of administering an oily drug and a non-oily drug at the same time, by filling a gel drug and a solid drug in one capsule. CONSTITUTION:100pts.wt. of a gelling base preferably a medium-chain fatty acid triglyceride (e.g. capric acid triglyceride) is mixed with 5-10pts.wt. of ethylcellulose to obtain a gel base, which is mixed with a drug. The pharmaceutical composition obtained above and a solid drug are filled in a hard capsule in an arbitrary order, left at rest at a normal temperature to gelatinize the pharmaceutical composition and fix the solid drug in the capsule. Usually an oily drug is used as the gel drug and a non-oily drug as the solid drug, however, a desirable effect can be attained when two kinds of oily drugs which are incompatible with each other are applied in the above process.
INTRODUCTION: Bacterial meningitis poses significant medical challenges due to its acute inflammatory nature and potential for severe neurological complications, emphasizing the need for prompt diagnosis and treatment. Limited data exists on its epidemiology and antimicrobial resistance trends among hospitalized patients in Saudi Arabia. This study aimed to investigate these factors at a tertiary care hospital over six years.
METHODS: A retrospective analysis was conducted on cerebrospinal fluid samples results from 222 bacterial meningitis cases among hospitalized patients between 2018 and 2023. Demographic, clinical, microbiological data, and antibiotic susceptibility patterns were collected and analyzed.
RESULTS: Pseudomonas aeruginosa (43%) was the predominant pathogen isolated. Neonates (16%) and children (47%) were most affected population. Nosocomial meningitis accounted for 92% of cases, mainly in the intensive care settings (50.45%). Extended-spectrum beta-lactamase was the leading resistance pattern (12.2%). Seasonal variation was observed, with a peak incidence in October-November.
CONCLUSION: The study highlights the substantial burden of bacterial meningitis among hospitalized patients, especially among high-risk groups. Emerging antimicrobial resistance emphasizes the need for optimized surveillance and stewardship. Future prospective research employing molecular techniques across multiple centers in the country is warranted to enhance understanding and guide public health strategies in Saudi Arabia.
RECOTHROM Thrombin topical (Recombinant) was evaluated in a randomized, double-blind comparative clinical trial to bovine thrombin. Each thrombin was topically applied to bleeding sites with an absorbable gelatin sponge at a nominal concentration of 1000 units/mL.1 Patients (N=411) were a heterogeneous surgical population undergoing surgery in one of four surgical settings: spinal surgery (n=122, 30%), hepatic resection (n=125, 30%), peripheral arterial bypass surgery (n=88, 21%), and arteriovenous graft formation for hemodialysis access (n=76, 18%). Patients with prior heparin-induced thrombocytopenia were excluded. Patient ages ranged from 21 to 89 years, gender was 53% male and 47% female, and the distribution by race was 68% white, 18% black or African American, and 14% other. The distribution of these characteristics was similar in both the RECOTHROM and bovine thrombin treatment groups. 

The objectives of the study were to evaluate the comparative efficacy, safety, and immunogenicity of RECOTHROM and bovine thrombin in combination with an absorbable gelatin sponge as adjuncts to hemostasis in surgery. Efficacy was evaluated by the incidence of hemostasis within 10 minutes. Bleeding appropriate for evaluation was defined as mild to moderate bleeding, either on its own or remaining after brisk bleeding was controlled by standard surgical modalities. Although multiple bleeding sites could be treated, only one bleeding site per patient was selected to determine effectiveness.

Table 2 summarizes the incidence of hemostasis within 10 minutes for each treatment for the 401  
efficacy evaluable patients. The incidence of hemostasis within 10 minutes was comparable for the   
RECOTHROM and bovine thrombin groups.

The percentage of patients achieving hemostasis at 1.5, 3, 6, and 10 minutes is listed in Table 3.
I started my journey as a nutrition scholar in 1974 when I began PhD studies at Cornell University. My journey has been rich with opportunity. I engaged in research on diet-related risks for cardiovascular diseases, diabetes, and cancer, partly motivated by my strong commitment to addressing health disparities affecting Black Americans. Obesity became my major focus and would eventually involve both US and global lenses. This focus was also linked to other dietary intake issues and health disparities and drew on knowledge I had gained in my prior study and practice of social work. I positioned myself as a bridge builder across nutrition, epidemiology, and public health, advocating for certain new ways of thinking and acting in these spheres and in the academy itself. Life skills honed during my formative years living within racially segregated contexts have been critical to any successes I have achieved.
The ability of ticlopidine to reduce the rate of thrombotic events after the placement of coronary artery stents has been studied in five randomized trials, one of substantial size (Stent Anticoagulation Restenosis Study or STARS) described below, and four smaller studies. In these trials, ticlopidine 250 mg bid with ASA (dose range from 100 mg bid to 325 mg qd) was compared to aspirin alone or to anticoagulant therapy plus aspirin. The trials enrolled patients undergoing both planned (elective) and unplanned coronary stent placement. The types of stents used, the use of intravascular ultrasound, and the use of high-pressure stent deployment varied among the trials, although all patients in STARS received a Palmaz-Schatz stent. The primary efficacy endpoints of the trials were similar, and included death, myocardial infarction and the need for repeat coronary angioplasty or CABG. All trials followed patients for at least 30 days.

In STARS, patients were randomized to receive one of three regimens for 4 weeks: aspirin alone, aspirin plus coumadin, or aspirin plus ticlopidine. Therapy was initiated following successful coronary stent placement. The primary endpoint was the incidence of stent thrombosis, defined as death, Q-Wave MI, or angiographic thrombus within the stented vessel demonstrated at the time of documented ischemia requiring emergent revascularization. The incidence rates for the primary endpoint and its components at 30 days are shown in the table below.

The use of ticlopidine plus aspirin did not affect the rate of non-Q-wave MIs when compared with aspirin alone or aspirin plus anticoagulants in STARS.

The use of ticlopidine plus aspirin was associated with a lower rate of recurrent cardiovascular events when compared with aspirin alone or aspirin plus anticoagulants in the other four randomized trials.

The rate of serious bleeding complications and neutropenia in STARS are shown in the table below. There were no cases of thrombotic thrombocytopenic purpura (TTP) or aplastic anemia reported in 1346 patients who received ticlopidine plus aspirin in the five randomized trials.
In this, randomized controlled trial, mild to moderate hyperlipidemic subjects were randomly divided into 2 groups as walnut-enriched (n=20) and control (n=17) groups for 6 weeks. All subjects adhered to a medical nutrition therapy as low-fat and low-cholesterol diet. The walnut-enriched group was supplemented with 40 g/day of walnuts added to their diets. In order to follow nutritional status of subjects, they were visited every 15 days (in total 4 times). Anthropometric measurements of the subjects were taken and were monitored at each visit during the study. Blood samples were measured at the beginning and again at the end of the study.
The second group included 28 patients who had undergone MH surgery with C3F8 gas and who were advised to maintain a face-down position for 14 days. Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.